Shares soared 25%, AnPac Bio-Medical on first disease treatment US patent
Shares soared 25%, AnPac Bio-Medical on first disease treatment US patent
$AnPac Bio-Medical Science(ANPC.US)$ has received its first disease treatment patent by the United States Patent and Trademark Office.
$Anpac生物醫學科學(ANPC.US)$已獲得美國專利商標局的首項疾病治療專利。
The patent covers novel medical devices for both disease detection and treatment applications and has 25 claims.
The patent covers novel device structures and methods to modify biological samples for treatment purposes. This latest patent is the 21st patent granted to AnPac Bio in the U.S.
The Company also announced that its newly launched cancer treatment joint venture has secured, via signed legal documents, over $4 million of capital contributions from multiple funding sources.
The funding will be used to fabricate cancer treatment medical devices and the device's subsequent laboratory tests this year.
Price Action: ANPC shares are up 25% at $5.42 during the premarket trading session on the last check Friday.
該專利涵蓋了用於疾病檢測和治療的新型醫療設備，並提出了25項權利要求。
該專利涵蓋了為治療目的而修改生物樣本的新型裝置結構和方法。這項最新專利是安帕克生物公司在美國獲得的第21項專利。
該公司還宣佈，其新成立的癌症治療合資企業已通過簽署的法律文件從多個資金來源獲得400多萬美元的出資。
這筆資金將用於製造癌症治療醫療設備，以及今年該設備隨後的實驗室測試。
價格行動：在週五最後一次盤前交易中，ANPC股價上漲25%，至5.42美元。